Trifluridinetipiracil receives marketing authorisation in Europe for patients with previously treated metastatic gastric cancer

Trifluridine/tipiracil receives marketing authorisation in Europe for patients with previously treated metastatic gastric cancer

The European Commission (EC) has approved the use of trifluridine/tipiracil as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with...

More From BioPortfolio on "Trifluridine/tipiracil receives marketing authorisation in Europe for patients with previously treated metastatic gastric cancer"